I am an investor

I want to know more about Cantargia's research

I want to know more about Cantargia as a company

Cantargia in a panel discussion on how to build a successful biotech company

Panel discussion (in Swedish)

CEO Interview after direct share issue

To the interview (in Swedish)

CEO presentation

To the presentation (in Swedish)

Presentation at ASCO 2019, follow up articles and interviews

A brief introduction to Cantargia

To the interview

Press releases

2021-03-19 (R) Cantargia reports positive preclinical safety and efficacy results in the CAN10 project

2021-03-10 (R) Cantargia submits application to start new clinical trial investigating antibody CAN04 and FOLFIRINOX in pancreatic can

2021-03-01 Cantargia provides business updates at investor conferences during March 2021

(R) = Regulatory press releases

”Looking back at the past year, Cantargia now stands on even firmer ground than we did a year ago, despite everything. We have made progress both on our main project, CAN04, and on our second project, CAN10.”

Göran Forsberg

CEO Cantargia

Analysis

2021-04-06, Edison analysis of Cantargia

2021-03-10, Edison analysis of Cantargia

2021-02-26, Nordea analysis of Cantargia

2021-02-15, Aktiespararna analysis of Cantargia (In Swedish)

Presentations